These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 2133250)
41. Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer. Schmitt M; Goretzki L; Jänicke F; Calvete J; Eulitz M; Kobayashi H; Chucholowski N; Graeff H Biomed Biochim Acta; 1991; 50(4-6):731-41. PubMed ID: 1801751 [TBL] [Abstract][Full Text] [Related]
42. Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma. Speleman L; Kerrebijn JD; Look MP; Meeuwis CA; Foekens JA; Berns EM Head Neck; 2007 Apr; 29(4):341-50. PubMed ID: 17163465 [TBL] [Abstract][Full Text] [Related]
43. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Jänicke F; Schmitt M; Pache L; Ulm K; Harbeck N; Höfler H; Graeff H Breast Cancer Res Treat; 1993; 24(3):195-208. PubMed ID: 8435475 [TBL] [Abstract][Full Text] [Related]
44. [Urokinase-type plasminogen activator as a predictor for lymph nodes metastasis of uterine cervical cancer]. Fujishiro S; Kobayashi H; Terao T Nihon Sanka Fujinka Gakkai Zasshi; 1994 Feb; 46(2):129-36. PubMed ID: 8126385 [TBL] [Abstract][Full Text] [Related]
45. Cathepsin D and prognosis in breast cancer. Tandon AK; Clark GM; Chamness GC; Chirgwin JM; McGuire WL N Engl J Med; 1990 Feb; 322(5):297-302. PubMed ID: 2296271 [TBL] [Abstract][Full Text] [Related]
46. Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Kute TE; Shao ZM; Sugg NK; Long RT; Russell GB; Case LD Cancer Res; 1992 Oct; 52(19):5198-203. PubMed ID: 1394123 [TBL] [Abstract][Full Text] [Related]
47. [tPA, uPA, PAI-1 as prognostic factors of breast cancers]. Shiba E; Kim SJ Nihon Rinsho; 2000 Apr; 58 Suppl():429-34. PubMed ID: 11026029 [No Abstract] [Full Text] [Related]
48. Tumour budding, uPA and PAI-1 are associated with aggressive behaviour in colon cancer. Märkl B; Renk I; Oruzio DV; Jähnig H; Schenkirsch G; Schöler C; Ehret W; Arnholdt HM; Anthuber M; Spatz H J Surg Oncol; 2010 Sep; 102(3):235-41. PubMed ID: 20740581 [TBL] [Abstract][Full Text] [Related]
49. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Duffy MJ; Reilly D; O'Sullivan C; O'Higgins N; Fennelly JJ; Andreasen P Cancer Res; 1990 Nov; 50(21):6827-9. PubMed ID: 2119883 [TBL] [Abstract][Full Text] [Related]
51. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Harbeck N; Thomssen C; Berger U; Ulm K; Kates RE; Höfler H; Jänicke F; Graeff H; Schmitt M Breast Cancer Res Treat; 1999 Mar; 54(2):147-57. PubMed ID: 10424405 [TBL] [Abstract][Full Text] [Related]
52. Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours. Santos A; Lopes C; Marques RM; Amorim I; Ribeiro J; Frias C; Vicente C; Gärtner F; de Matos A Vet J; 2011 Jul; 189(1):43-8. PubMed ID: 20598596 [TBL] [Abstract][Full Text] [Related]
53. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L. Thomssen C; Oppelt P; Jänicke F; Ulm K; Harbeck N; Höfler H; Kuhn W; Graeff H; Schmitt M Anticancer Res; 1998; 18(3C):2173-80. PubMed ID: 9703780 [TBL] [Abstract][Full Text] [Related]
54. A new look at node-negative breast cancer. Harbeck N; Thomssen C Oncologist; 2010; 15 Suppl 5():29-38. PubMed ID: 21138953 [TBL] [Abstract][Full Text] [Related]
55. Urokinase-type plasminogen activator in human aqueous humor. Bernatchez SF; Tabatabay C; Belin D Invest Ophthalmol Vis Sci; 1992 Aug; 33(9):2687-92. PubMed ID: 1639615 [TBL] [Abstract][Full Text] [Related]
56. [D-dimer and plasminogen activator of the urokinase type: personal experiences with breast cancer]. Neises M; Schäfer T; Strittmatter HJ; Wischnik A; Dettmar P; Melchert F Geburtshilfe Frauenheilkd; 1993 Jul; 53(7):455-60. PubMed ID: 8370485 [TBL] [Abstract][Full Text] [Related]
57. Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue. Costantini V; Zacharski LR; Memoli VA; Kudryk BJ; Rousseau SM; Stump DC Cancer Res; 1991 Jan; 51(1):354-8. PubMed ID: 1846311 [TBL] [Abstract][Full Text] [Related]
58. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma]. Göhring UJ; Scharl A; Ahr A Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282 [TBL] [Abstract][Full Text] [Related]
59. RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene. Muehlenweg B; Schnelzer A; Türkmen B; Lengyel E; Reuning U; Graeff H; Schmitt M; Magdolen V Methods Mol Med; 2001; 39():299-306. PubMed ID: 21340784 [TBL] [Abstract][Full Text] [Related]
60. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis. Schmitt M; Wilhelm O; Jänicke F; Magdolen V; Reuning U; Ohi H; Moniwa N; Kobayashi H; Weidle U; Graeff H J Obstet Gynaecol (Tokyo 1995); 1995 Apr; 21(2):151-65. PubMed ID: 8556577 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]